Welcome to this week's Chutes and Ladders, our roundup of hirings and firings throughout the industry. Please send the good word--or the bad--from your shop to Michael Gibney (email | Twitter) or Emily Mullin (email | Twitter) and we will feature it here at the end of each week.
Eli Lilly's board elects multinational financial leader
The board of directors at Eli Lilly ($LLY) has elected Jackson Tai as its newest member. Tai serves as a nonexecutive director of The Bank of China, Singapore Airlines, NYSE Euronext, MasterCard and Royal Philips NV. Lilly CEO John Lechleiter said in a statement: "Mr. Tai brings to the Lilly board extensive experience in international business and finance, including serving as the CEO of a major multinational financial institution and as a board member of several leading global companies. Having lived and worked in Japan and Singapore for almost 15 years, Jack has a deep understanding of the Asia-Pacific region that will be particularly helpful as our business in Asia continues to grow." Release
|
||||||||||||
Biotech
> Dr. Laurie Smaldone Alsup, chief scientific officer at PharmApprove, has been elected to KaloBios Pharmaceuticals' ($KBIO) board of directors. Release
> Drs. Benjamin Carson and Jan Vermorken have joined the medical advisory board of Vaccinogen. Release
> OvaScience ($OVAS) has appointed Dr. Hugh Taylor to the company's scientific advisory board. Taylor is the Anita O'Keeffe Young Professor of Obstetrics, Gynecology, and Reproductive Sciences; professor of molecular, cellular and developmental biology at the Yale School of Medicine; and chief of obstetrics and gynecology at Yale-New Haven Hospital. Release
> Five Prime Therapeutics ($FPRX) has appointed Aron Knickerbocker, senior vice president and chief business officer of Five Prime, to the company's board of directors and Marc Belsky to the position of chief financial officer. Belsky and Knickerbocker both joined the company in 2009. Release
> Immune Design has appointed Dr. Frank Hsu as vice president, head of oncology. Hsu recently served as chief medical officer for Zyngenia. Release
> Celsus Therapeutics has appointed Dr. Pablo Jimenez to the position of chief medical officer. Jimenez previously held various positions at Novartis ($NVS). Release
> Harvard Bioscience appointed Yoav Sibony as its vice president of global sales. Release
> BioDelivery Sciences ($BDSI) brought on Ernest De Paolantonio as its chief financial officer. De Paolantonio previously served as CFO of CorePharma. Release
> Bruin Biometrics appointed Jeff Greiner and Eve Kurtin to its board of directors. Release
> Dan Calvo took the helm as CEO of Gyros AB, replacing Erik Walldén, who stepped down. Release
> PATH appointed Ashley Birkett as director of its Malaria Vaccine Initiative. Birkett was most recently the program's deputy director. Release
Pharma
> Mallinckrodt ($MNK) has made three new appointments to its senior management team: Hugh O'Neill will serve as senior vice president and president of specialty pharmaceuticals; Gary Phillips will be senior vice president and chief strategy officer; and Mario Saltarelli has joined as senior vice president and chief science officer. Release
> Daniel Swisher, CEO of Sunesis Pharmaceuticals ($SNSS), joined Cerus' board of directors. Release
> Dominic Blakemore joined Shire's ($SHPG) board of directors. Previously, Blakemore was CFO at Iglo Foods Group and Finance & Strategy Director at Cadbury. Release
Medical Devices
> Dr. George Lopez is stepping down from the position of president and CEO of ICU Medical. Steven Riggs, vice president of operations, will step in as acting CEO. Release